A clinical study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in comparison to ProHance 'Registered trade mark' (gadoteridol) 0.5 molar in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system.
A multicenter, randomized, double-blind, crossover, phase 3 study to determine the safety and efficacy of gadobutrol 1.0 molar (Gadovist 'Registered trade mark') in patients referred for contrast-enhanced Magnetic Resonance Imaging (MRI) of the central nervous system (CNS). Protocol number 310123
Bayer Australia Ltd
402 participants
Jun 11, 2008
Interventional
Conditions
Summary
This study involves the use of Magnetic Resonance Imaging (MRI) contrast agents called gadobutrol (Gadovist®) Injection and ProHance® Injection. The purpose of this study is to look at the safety (what are the side effects) and efficacy (how well does it work) of gadobutrol when used for taking MR images of the brain and spine. The results of the MRI with gadobutrol Injection will be compared to the results of MR images taken without contrast and with the results of the MR images taken with ProHance®.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Drug: Gadovist 'Registered trade mark' (Gadobutrol) 1.0 molar; dose 0.1 mmol/kg; route of administration intravenous; duration of treatment is single dose;washout period 24 hours; MRI using steady state sequences.
Locations(7)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12608000455369